Glossary
The state-of-the-art glossary for Waldenström’s macroglobulinemia.
Proteasome inhibitors
Proteasome inhibitors in the glossary for Waldenström's macroglobulinemia
Drugs that block the action of proteasomes (cellular complexes that break down proteins)
Proteasome inhibitors are drugs that block the action of proteasomes (cellular complexes that break down proteins). They are being studied in the treatment of cancer; and three are approved for use in treating multiple myeloma. Proteasome inhibition may prevent degradation of pro-apoptotic factors such as the p53 protein, permitting activation of programmed cell death in neoplastic cells dependent upon suppression of pro-apoptotic pathways. Bortezomib, carfilzomib and ixazomib are approved proteasome inhibitors, with several others in clinical trials.
Glossary overview